Share
When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Manage episode 515120812 series 2395115
Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In today’s episode, we had the pleasure of speaking with Eunice Wang, MD, about the secondary AML treatment paradigm. Dr Wang is a professor of oncology, leader of the Leukemia Clinical Disease Team, chief of leukemia in the Department of Medicine, and an assistant member of the Tumor Immunology Program in the Department of Immunology at Roswell Park Comprehensive Cancer Center in Buffalo, New York; as well as an associate professor in the Department of Medicine and an academic scholar at the Jacobs School of Medicine and Biomedical Sciences at the State University of New York at Buffalo.
In our exclusive interview, Dr Wang discussed the prevalence of secondary AML, and explained that this population lacks standard therapies, often relying on allogeneic stem cell transplantation. She noted that CPX-351, a liposomal formulation of cytarabine and daunorubicin, has generated improved outcomes compared with 7+3 chemotherapy in this population. She also highlighted future research, which includes targeted therapies and less intensive regimens.
In our exclusive interview, Dr Wang discussed the prevalence of secondary AML, and explained that this population lacks standard therapies, often relying on allogeneic stem cell transplantation. She noted that CPX-351, a liposomal formulation of cytarabine and daunorubicin, has generated improved outcomes compared with 7+3 chemotherapy in this population. She also highlighted future research, which includes targeted therapies and less intensive regimens.
700 episodes
))
